New Zealand markets open in 8 hours 42 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7997-0.0078 (-0.97%)
At close: 04:00PM EDT
0.8000 +0.00 (+0.04%)
Pre-market: 09:18AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 48.59M
Enterprise value 8.91M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.53
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.11

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3-94.39%
S&P500 52-week change 3-4.45%
52-week high 318.3000
52-week low 30.4900
50-day moving average 30.6191
200-day moving average 32.9614

Share statistics

Avg vol (3-month) 33.32M
Avg vol (10-day) 33.08M
Shares outstanding 566.64M
Implied shares outstanding 6N/A
Float 838.31M
% held by insiders 148.25%
% held by institutions 116.63%
Shares short (28 Jul 2022) 41.58M
Short ratio (28 Jul 2022) 40.3
Short % of float (28 Jul 2022) 44.27%
Short % of shares outstanding (28 Jul 2022) 42.37%
Shares short (prior month 29 Jun 2022) 41.68M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-231.52%
Return on equity (ttm)-425.62%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -105.89M
Net income avi to common (ttm)-336.84M
Diluted EPS (ttm)-6.2470
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)40.2M
Total cash per share (mrq)0.6
Total debt (mrq)520k
Total debt/equity (mrq)1.64
Current ratio (mrq)3.66
Book value per share (mrq)0.48

Cash flow statement

Operating cash flow (ttm)-45.07M
Levered free cash flow (ttm)-55.66M